Novozymes A/S sells patents to Solvay Pharmaceuticals

As of 19 December 2002 Solvay has acquired the patents related to the production of a recombinant enzyme for pharmaceutical specialities.

As of 19 December 2002 Solvay has acquired the patents related to the production of a recombinant enzyme for pharmaceutical specialities. Novozymes has retained the right to develop, manufacture and market the specific enzyme outside this field.
 
Novozymes will receive a minor up-front payment this year for disposal of the patents. If Solvay markets the specific enzyme covered by the patented technology, Novozymes is entitled to royalty payment based on the net sales.  
 
Long-term strategy
The agreement highlights the breadth of Novozymes’ strong patent portfolio within proteins and underlines Novozymes’ strategy to commercialize and exploit ideas in which Novozymes’ technologies can play a role.
 
Outlook for 2002
The agreement will have a slightly positive impact on this year's operating profit.
 
Contacts:
Media:                                               Investors:
Eva Louise Holm Petersen                    Michael Steen-Knudsen
Tel. (direct): +45 4442 3338                Tel. (direct): +45 4442 6048
                                                                        
                                                         Thomas Kudsk Larsen                
                                                         Tel. (direct): +45 4442 5969